Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting
August 09 2017 - 7:30AM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that there will be four
presentations and two posters on ILUVIEN® at the 2017 American
Society of Retinal Specialists (ASRS) Annual Meeting to be held
August 11 through 15 in Boston.
"We look forward to the pivotal trial and real world evidence
data on ILUVIEN being presented this year at ASRS, as it highlights
the benefits of continuous microdosing,” said Dan Myers, CEO of
Alimera. "These presentations highlight the ability for patients to
reach driving vision and present visual outcomes achieved over
time. Additionally, there will be data presented on the
predictability and manageability of potential side effects from two
large studies, one retrospective and one prospective."
Presentations:
Sunday, August 13, 2017, 1:13pm
- Inhibition of Diabetic Retinopathy Progression by 0.2 μg/day
Fluocinolone Acetonide Implants: A Fellow-Eye Controlled Analysis.
Raymond Iezzi, MD, MS Associate Professor of Ophthalmology, Mayo
Clinic Department of Ophthalmology, Rochester, MN
Sunday, August 13, 2017, 1:27pm
- Long-Term Visual Acuity Response in Early Nonresponders Treated
With 0.2 μg/day Fluocinolone Acetonide Implants in FAME Study.
Daniel Roth, MD, Associate Clinical Professor, NJ Retina – Retina
Vitreous Center, Department of Ophthalmology, Rutgers Robert Wood
Johnson Medical School, New Brunswick, NJ
Sunday, August 13, 2017, 4:03pm
- Predictability of IOP Response in Patients Receiving Prior
Steroid and Subsequent 0.2 μg/day Fluocinolone Acetonide
Intravitreal Implant Therapy. Seenu Hariprasad, MD, Shui-Chin Lee
Professor of Ophthalmology, Chief, Vitreoretinal Service, Director
of Clinical Research, University of Chicago Department of
Ophthalmology
Sunday August 13, 2017, 4:08pm
- Initial Efficacy, Anatomic and Safety Outcomes After
Fluocinolone Acetonide 0.2 μg/Day Implant in DME: The PALADIN
Real-World Observational Study. Jay Prensky, MD, FACS,
Pennsylvania Retina Specialists, PC, Camp Hill, PA
Posters:
- The CONSTANT analysis: area-under-the-curve evaluation
comparing fluocinolone acetonide 0.2 μg/day with ranibizumab over a
36-month study period (Poster # 214). Jeffrey Gross, MD, Founder,
Carolina Retina Center, 7620 Trenholm Rd., Columbia, SC
- Effect of Fluocinolone Acetonide 0.2μg/Day Implant on the
Decision to Drive in Patients with Diabetic Macular Edema: Report
from FAME Trial, (Poster on Demand). Dilraj Grewal, MD, Associate
Professor of Ophthalmology, Duke Eye Center, Duke University School
of Medicine, 2351 Erwin Road, Durham, NC
About ILUVIEN
www.ILUVIEN.com.
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S. to
treat diabetic macular edema in patients who have been previously
treated with a course of corticosteroids and did not have a
clinically significant rise in intraocular pressure. Each ILUVIEN
implant is designed to release submicrogram levels of fluocinolone
acetonide, a corticosteroid, for 36 months.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME. As
the population of people with diabetes increases, Alimera expects
the annual incidence of diagnosed DME to increase, as well.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company
that specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
Alimera’s commitment to retina specialists and their patients is
manifest in Alimera’s product and development portfolio designed to
treat early- and late-stage diseases. For more information, please
visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024